BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37108089)

  • 1. Unveiling the Genomic Basis of Chemosensitivity in Sarcomas of the Extremities: An Integrated Approach for an Unmet Clinical Need.
    Vanni S; Fausti V; Fonzi E; Liverani C; Miserocchi G; Spadazzi C; Cocchi C; Calabrese C; Gurrieri L; Riva N; Recine F; Casadei R; Pieri F; Guerrieri AN; Serra M; Ibrahim T; Mercatali L; De Vita A
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma.
    Crago AM; Cardona K; Koseła-Paterczyk H; Rutkowski P
    Surg Oncol Clin N Am; 2022 Jul; 31(3):419-430. PubMed ID: 35715142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival.
    Li GZ; Okada T; Kim YM; Agaram NP; Sanchez-Vega F; Shen Y; Tsubokawa N; Rios J; Martin AS; Dickson MA; Qin LX; Socci ND; Singer S
    Cancer Res; 2020 Jun; 80(12):2461-2471. PubMed ID: 32161142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelioid variant of myxofibrosarcoma: expanding the clinicomorphologic spectrum of myxofibrosarcoma in a series of 17 cases.
    Nascimento AF; Bertoni F; Fletcher CD
    Am J Surg Pathol; 2007 Jan; 31(1):99-105. PubMed ID: 17197925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma.
    Lewin J; Garg S; Lau BY; Dickson BC; Traub F; Gokgoz N; Griffin AM; Ferguson PC; Andrulis IL; Sim HW; Kamel-Reid S; Stockley TL; Siu LL; Wunder JS; Razak ARA
    Int J Cancer; 2018 Jan; 142(1):57-65. PubMed ID: 28891048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A League of Its Own? Established and Emerging Therapies in Undifferentiated Pleomorphic Sarcoma.
    Graves L; Jeck WR; Grilley-Olson JE
    Curr Treat Options Oncol; 2023 Mar; 24(3):212-228. PubMed ID: 36729198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential.
    Francis P; Namløs HM; Müller C; Edén P; Fernebro J; Berner JM; Bjerkehagen B; Akerman M; Bendahl PO; Isinger A; Rydholm A; Myklebost O; Nilbert M
    BMC Genomics; 2007 Mar; 8():73. PubMed ID: 17359542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of undifferentiated pleomorphic sarcoma of the chest wall.
    Bennett C; Bharadwaj S; Arndt A; Chawla A
    Chin Clin Oncol; 2023 Dec; 12(6):66. PubMed ID: 38073309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Undifferentiated pleomorphic sarcoma: Factors predictive of adverse outcomes.
    Winchester D; Lehman J; Tello T; Chimato N; Hocker T; Kim S; Chang J; Markey J; Yom SS; Ryan W; Mully T; Hodge D; Otley C; Arron ST
    J Am Acad Dermatol; 2018 Nov; 79(5):853-859. PubMed ID: 29787841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma.
    Nakayama R; Nemoto T; Takahashi H; Ohta T; Kawai A; Seki K; Yoshida T; Toyama Y; Ichikawa H; Hasegawa T
    Mod Pathol; 2007 Jul; 20(7):749-59. PubMed ID: 17464315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Study of Myxofibrosarcoma With Undifferentiated Pleomorphic Sarcoma: Histopathologic and Clinicopathologic Review.
    Yoshimoto M; Yamada Y; Ishihara S; Kohashi K; Toda Y; Ito Y; Yamamoto H; Furue M; Nakashima Y; Oda Y
    Am J Surg Pathol; 2020 Jan; 44(1):87-97. PubMed ID: 31651522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pleomorphic Liposarcoma: A Series of 120 Cases With Emphasis on Morphologic Variants.
    Gjorgova Gjeorgjievski S; Thway K; Dermawan JK; John I; Fisher C; Rubin BP; Jenkins S; Thangaiah JJ; Folpe AL; Fritchie KJ
    Am J Surg Pathol; 2022 Dec; 46(12):1700-1705. PubMed ID: 36006773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-cancer Genomic Analysis of AXL Mutations Reveals a Novel, Recurrent, Functionally Activating AXL W451C Alteration Specific to Myxofibrosarcoma.
    Williams EA; Vegas I; El-Senduny FF; Zhang J; Mata DA; Hiemenz MC; Hughes SR; Sa BC; Kraft GP; Gorbatov N; Foley-Peres K; Sanchez EZ; Milikowski C; Williams KJ; Ross JS; Kurzrock R; Montgomery EA; Lombard DB; Kumar S
    Am J Surg Pathol; 2024 Jun; 48(6):699-707. PubMed ID: 38369783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives.
    Vanni S; De Vita A; Gurrieri L; Fausti V; Miserocchi G; Spadazzi C; Liverani C; Cocchi C; Calabrese C; Bongiovanni A; Riva N; Mercatali L; Pieri F; Casadei R; Lucarelli E; Ibrahim T
    Ther Adv Med Oncol; 2022; 14():17588359221093973. PubMed ID: 35782752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma.
    Orth MF; Gerke JS; Knösel T; Altendorf-Hofmann A; Musa J; Alba-Rubio R; Stein S; Hölting TLB; Cidre-Aranaz F; Romero-Pérez L; Dallmayer M; Baldauf MC; Marchetto A; Sannino G; Knott MML; Wehweck F; Ohmura S; Li J; Hakozaki M; Kirchner T; Dandekar T; Butt E; Grünewald TGP
    Int J Cancer; 2019 Feb; 144(4):859-867. PubMed ID: 30267407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
    Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
    Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting the prognosis of undifferentiated pleomorphic soft tissue sarcoma: a 20-year experience of 266 cases.
    Vodanovich DA; Spelman T; May D; Slavin J; Choong PFM
    ANZ J Surg; 2019 Sep; 89(9):1045-1050. PubMed ID: 31364245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Periostin and Epithelial-Mesenchymal Transition Score as Novel Prognostic Markers for Leiomyosarcoma, Myxofibrosarcoma, and Undifferentiated Pleomorphic Sarcoma.
    Piano MA; Brunello A; Cappellesso R; Del Bianco P; Mattiolo A; Fritegotto C; Montini B; Zamuner C; Del Fiore P; Rastrelli M; Sommariva A; De Salvo GL; Montesco MC; Rossi CR; Zagonel V; Calabrò ML
    Clin Cancer Res; 2020 Jun; 26(12):2921-2931. PubMed ID: 32127392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment and characterization of NCC-UPS3-C1: a novel patient-derived cell line of undifferentiated pleomorphic sarcoma.
    Tsuchiya R; Yoshimatsu Y; Noguchi R; Sin Y; Ono T; Akiyama T; Sugaya J; Nakatani F; Kojima N; Yoshida A; Ohtori S; Kawai A; Kondo T
    Hum Cell; 2022 Jan; 35(1):384-391. PubMed ID: 34665443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Undifferentiated and dedifferentiated soft tissue neoplasms: Immunohistochemical surrogates for differential diagnosis.
    Thway K; Fisher C
    Semin Diagn Pathol; 2021 Nov; 38(6):170-186. PubMed ID: 34602314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.